348 related articles for article (PubMed ID: 24011867)
21. Inhibitors of cyclin dependent kinases: useful targets for cancer treatment.
Sharma PS; Sharma R; Tyagi R
Curr Cancer Drug Targets; 2008 Feb; 8(1):53-75. PubMed ID: 18288944
[TBL] [Abstract][Full Text] [Related]
22. The evolving role of cyclin-dependent kinase inhibitors in cancer management.
Shapiro GI
Clin Adv Hematol Oncol; 2017 Mar; 15(3):174-177. PubMed ID: 28398270
[No Abstract] [Full Text] [Related]
23. Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeutics.
Stone A; Sutherland RL; Musgrove EA
Crit Rev Oncog; 2012; 17(2):175-98. PubMed ID: 22471707
[TBL] [Abstract][Full Text] [Related]
24. Inhibitors of cyclin-dependent kinase modulators for cancer therapy.
Senderowicz AM
Prog Drug Res; 2005; 63():183-206. PubMed ID: 16265881
[TBL] [Abstract][Full Text] [Related]
25. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
[TBL] [Abstract][Full Text] [Related]
26. Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker SR; Mallinger A; Workman P; Clarke PA
Pharmacol Ther; 2017 May; 173():83-105. PubMed ID: 28174091
[TBL] [Abstract][Full Text] [Related]
27. New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy.
Bury M; Le Calvé B; Ferbeyre G; Blank V; Lessard F
Trends Cell Biol; 2021 May; 31(5):331-344. PubMed ID: 33676803
[TBL] [Abstract][Full Text] [Related]
28. CDK12: an emerging therapeutic target for cancer.
Lui GYL; Grandori C; Kemp CJ
J Clin Pathol; 2018 Nov; 71(11):957-962. PubMed ID: 30104286
[TBL] [Abstract][Full Text] [Related]
29. Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors.
Parua PK; Fisher RP
Nat Chem Biol; 2020 Jul; 16(7):716-724. PubMed ID: 32572259
[TBL] [Abstract][Full Text] [Related]
30. Promotion of apoptosis in cancer cells by selective purine-derived pharmacological CDK inhibitors: one outcome, many mechanisms.
Węsierska-Gądek J; Maurer M
Curr Pharm Des; 2011; 17(3):256-71. PubMed ID: 21348827
[TBL] [Abstract][Full Text] [Related]
31. Inhibitors of the Cyclin-Dependent Kinase and PIM Kinase Pathways in the Treatment of Myeloma.
Ramakrishnan VG; Kumar SK
Cancer J; 2016; 22(1):7-11. PubMed ID: 26841010
[TBL] [Abstract][Full Text] [Related]
32. Novel potent pharmacological cyclin-dependent kinase inhibitors.
Węsierska-Gądek J; Chamrád I; Kryštof V
Future Med Chem; 2009 Dec; 1(9):1561-81. PubMed ID: 21425979
[TBL] [Abstract][Full Text] [Related]
33. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography.
Nandi S; Dey R; Dey S; Samadder A; Saxena AK
Anticancer Agents Med Chem; 2022; 22(3):485-498. PubMed ID: 34503422
[TBL] [Abstract][Full Text] [Related]
34. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
Zeidner JF; Karp JE
Leuk Res; 2015 Dec; 39(12):1312-8. PubMed ID: 26521988
[TBL] [Abstract][Full Text] [Related]
35. Why (multi)targeting of cyclin-dependent kinases is a promising therapeutic option for hormone-positive breast cancer and beyond.
Węsierska-Gądek J; Mauritz M
Future Med Chem; 2016 Jan; 8(1):55-72. PubMed ID: 26692095
[TBL] [Abstract][Full Text] [Related]
36. Anticancer therapeutic strategies based on CDK inhibitors.
Esposito L; Indovina P; Magnotti F; Conti D; Giordano A
Curr Pharm Des; 2013; 19(30):5327-32. PubMed ID: 23394082
[TBL] [Abstract][Full Text] [Related]
37. Molecules inducing specific cyclin-dependent kinase degradation and their possible use in cancer therapy.
Zheng M; Zhang XY; Chen W; Xia F; Yang H; Yuan K; Yang P
Future Med Chem; 2024 Feb; 16(4):369-388. PubMed ID: 38288571
[TBL] [Abstract][Full Text] [Related]
38. Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development-Review.
Łukasik P; Załuski M; Gutowska I
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805800
[TBL] [Abstract][Full Text] [Related]
39. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
40. Recent advances on CDK inhibitors: An insight by means of in silico methods.
Tutone M; Almerico AM
Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
